Want to join the conversation?
$REGN and $SNY announced today that European Commission has approved Praluent (alirocumab) for lowering of low-density lipoprotein cholesterol in certain adults with hypercholesterolemia. Praluent was co-developed by $REGN and $SNY and will be available in a single-dose (75 mg or 150 mg) pre-filled pen that patients can self-administer.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th